IL6 and COVID-19: Assuming that subjects with severe infection can benefit from suppression of cytokine release syndrome, a large number of clinical trials aimed to investigate the efficacy of anti-inflammatory therapy including anti-IL-1, anti-IL-6 agents and steroids in patients with COVID-19 were started [6].